Coherus Oncology (CHRS) Competitors

$1.48 -0.02 (-1.01%)

As of 12:43 PM Eastern

CHRS vs. SEPN, SVRA, CVAC, AKTS, and ALVO

Should you buy Coherus Oncology stock or one of its competitors? MarketBeat compares Coherus Oncology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Coherus Oncology include Septerna (SEPN), Savara (SVRA), CureVac (CVAC), Aktis Oncology (AKTS), and Alvotech (ALVO). These companies are all part of the "pharmaceutical products" industry.

How does Coherus Oncology compare to Septerna?

Septerna (NASDAQ:SEPN) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Septerna had 10 more articles in the media than Coherus Oncology. MarketBeat recorded 16 mentions for Septerna and 6 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.45 beat Septerna's score of -0.32 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Septerna currently has a consensus price target of $43.13, indicating a potential upside of 60.55%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 487.57%. Given Coherus Oncology's higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has a net margin of 397.30% compared to Septerna's net margin of -49.88%. Septerna's return on equity of -12.72% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Coherus Oncology	397.30%	-198.90%	-46.65%

72.8% of Coherus Oncology shares are held by institutional investors. 4.3% of Septerna shares are held by insiders. Comparatively, 8.1% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Septerna has a beta of 2.21, suggesting that its stock price is 121% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Coherus Oncology has higher revenue and earnings than Septerna. Septerna is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	26.35	-$48.88M	-$0.81	N/A
Coherus Oncology	$46.88M	4.85	$168.02M	$1.67	0.88

Summary

Coherus Oncology beats Septerna on 9 of the 17 factors compared between the two stocks.

How does Coherus Oncology compare to Savara?

Coherus Oncology (NASDAQ:CHRS) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

72.8% of Coherus Oncology shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Coherus Oncology has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$46.88M	4.85	$168.02M	$1.67	0.88
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Coherus Oncology presently has a consensus target price of $8.67, suggesting a potential upside of 487.57%. Savara has a consensus target price of $9.13, suggesting a potential upside of 92.31%. Given Coherus Oncology's higher probable upside, equities research analysts plainly believe Coherus Oncology is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Coherus Oncology has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market. Comparatively, Savara has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market.

In the previous week, Savara had 12 more articles in the media than Coherus Oncology. MarketBeat recorded 18 mentions for Savara and 6 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.45 beat Savara's score of -0.79 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Coherus Oncology has a net margin of 397.30% compared to Savara's net margin of 0.00%. Savara's return on equity of -87.19% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Savara	N/A	-87.19%	-66.42%

Summary

Coherus Oncology beats Savara on 10 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to CureVac?

CureVac (NASDAQ:CVAC) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Coherus Oncology had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Coherus Oncology and 0 mentions for CureVac. Coherus Oncology's average media sentiment score of 0.45 beat CureVac's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Coherus Oncology	Neutral

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

CureVac presently has a consensus target price of $6.83, indicating a potential upside of 46.64%. Coherus Oncology has a consensus target price of $8.67, indicating a potential upside of 487.57%. Given Coherus Oncology's stronger consensus rating and higher probable upside, analysts clearly believe Coherus Oncology is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has a net margin of 397.30% compared to CureVac's net margin of 199.92%. CureVac's return on equity of -23.03% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Coherus Oncology	397.30%	-198.90%	-46.65%

CureVac has higher revenue and earnings than Coherus Oncology. Coherus Oncology is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Coherus Oncology	$46.88M	4.85	$168.02M	$1.67	0.88

Summary

Coherus Oncology beats CureVac on 9 of the 16 factors compared between the two stocks.

How does Coherus Oncology compare to Aktis Oncology?

Coherus Oncology (NASDAQ:CHRS) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk, media sentiment and dividends.

Coherus Oncology has a net margin of 397.30% compared to Aktis Oncology's net margin of 0.00%. Aktis Oncology's return on equity of 0.00% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
Aktis Oncology	N/A	N/A	N/A

Coherus Oncology currently has a consensus target price of $8.67, suggesting a potential upside of 487.57%. Aktis Oncology has a consensus target price of $32.00, suggesting a potential upside of 71.92%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts clearly believe Coherus Oncology is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

72.8% of Coherus Oncology shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 8.1% of Coherus Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Coherus Oncology has higher revenue and earnings than Aktis Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$46.88M	4.85	$168.02M	$1.67	0.88
Aktis Oncology	$6.50M	152.91	N/A	N/A	N/A

In the previous week, Coherus Oncology had 4 more articles in the media than Aktis Oncology. MarketBeat recorded 6 mentions for Coherus Oncology and 2 mentions for Aktis Oncology. Coherus Oncology's average media sentiment score of 0.45 beat Aktis Oncology's score of 0.01 indicating that Coherus Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coherus Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aktis Oncology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Coherus Oncology beats Aktis Oncology on 8 of the 12 factors compared between the two stocks.

How does Coherus Oncology compare to Alvotech?

Alvotech (NASDAQ:ALVO) and Coherus Oncology (NASDAQ:CHRS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

Coherus Oncology has a net margin of 397.30% compared to Alvotech's net margin of -14.36%. Alvotech's return on equity of -11.92% beat Coherus Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	-14.36%	-11.92%	-7.58%
Coherus Oncology	397.30%	-198.90%	-46.65%

Alvotech has a beta of 0.21, suggesting that its stock price is 79% less volatile than the broader market. Comparatively, Coherus Oncology has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Alvotech presently has a consensus price target of $7.60, indicating a potential upside of 132.06%. Coherus Oncology has a consensus price target of $8.67, indicating a potential upside of 487.57%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	2 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Coherus Oncology has lower revenue, but higher earnings than Alvotech. Alvotech is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$586.32M	1.69	$27.92M	-$0.25	N/A
Coherus Oncology	$46.88M	4.85	$168.02M	$1.67	0.88

In the previous week, Coherus Oncology had 3 more articles in the media than Alvotech. MarketBeat recorded 6 mentions for Coherus Oncology and 3 mentions for Alvotech. Coherus Oncology's average media sentiment score of 0.45 beat Alvotech's score of 0.00 indicating that Coherus Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alvotech	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Coherus Oncology	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.8% of Coherus Oncology shares are owned by institutional investors. 0.5% of Alvotech shares are owned by company insiders. Comparatively, 8.1% of Coherus Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Coherus Oncology beats Alvotech on 13 of the 16 factors compared between the two stocks.

Get Coherus Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CHRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CHRS vs. The Competition

Export

Metric	Coherus Oncology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$227.52M	$3.27B	$6.29B	$12.07B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	0.88	18.49	20.62	25.05
Price / Sales	4.85	280.89	545.58	77.63
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	2.95	6.58	9.73	6.60
Net Income	$168.02M	$24.30M	$3.55B	$335.50M
7 Day Performance	-13.74%	-3.17%	-1.86%	-1.91%
1 Month Performance	-25.51%	-7.57%	-3.69%	-1.84%
1 Year Performance	84.38%	52.35%	29.52%	27.02%

Coherus Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CHRS Coherus Oncology	3.154 of 5 stars	$1.48 -1.0%	$8.67 +487.6%	+95.8%	$227.52M	$46.88M	0.88	330
SEPN Septerna	3.1615 of 5 stars	$23.57 -1.3%	$43.13 +83.0%	+167.3%	$1.07B	$45.95M	N/A	N/A	Earnings Report Upcoming Earnings
SVRA Savara	2.3137 of 5 stars	$5.12 -2.1%	$9.13 +78.2%	+59.9%	$1.07B	N/A	N/A	20	Positive News Earnings Report Analyst Revision
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880
AKTS Aktis Oncology	1.7111 of 5 stars	$18.27 -1.8%	$32.00 +75.2%	N/A	$993.30M	$6.50M	N/A	76

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CHRS) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Coherus Oncology (CHRS) Competitors

CHRS vs. SEPN, SVRA, CVAC, AKTS, and ALVO

How does Coherus Oncology compare to Septerna?

Summary

How does Coherus Oncology compare to Savara?

Summary

How does Coherus Oncology compare to CureVac?

Summary

How does Coherus Oncology compare to Aktis Oncology?

Summary

How does Coherus Oncology compare to Alvotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Coherus Oncology (CHRS) Competitors

CHRS vs. SEPN, SVRA, CVAC, AKTS, and ALVO

How does Coherus Oncology compare to Septerna?

Does the media prefer SEPN or CHRS?

Do analysts rate SEPN or CHRS?

Is SEPN or CHRS more profitable?

Do institutionals & insiders believe in SEPN or CHRS?

Which has more risk & volatility, SEPN or CHRS?

Which has stronger valuation & earnings, SEPN or CHRS?

Summary

How does Coherus Oncology compare to Savara?

Do institutionals and insiders have more ownership in CHRS or SVRA?

Which has higher valuation & earnings, CHRS or SVRA?

Do analysts prefer CHRS or SVRA?

Which has more risk & volatility, CHRS or SVRA?

Does the media favor CHRS or SVRA?

Is CHRS or SVRA more profitable?

Summary

How does Coherus Oncology compare to CureVac?

Do institutionals & insiders believe in CVAC or CHRS?

Does the media refer more to CVAC or CHRS?

Which has more risk & volatility, CVAC or CHRS?

Do analysts rate CVAC or CHRS?

Is CVAC or CHRS more profitable?

Which has stronger valuation and earnings, CVAC or CHRS?

Summary

How does Coherus Oncology compare to Aktis Oncology?

Is CHRS or AKTS more profitable?

Do analysts recommend CHRS or AKTS?

Do insiders and institutionals hold more shares of CHRS or AKTS?

Which has better earnings & valuation, CHRS or AKTS?

Does the media prefer CHRS or AKTS?

Summary

How does Coherus Oncology compare to Alvotech?

Is ALVO or CHRS more profitable?

Which has more risk and volatility, ALVO or CHRS?

Do analysts prefer ALVO or CHRS?

Which has preferable earnings & valuation, ALVO or CHRS?

Does the media refer more to ALVO or CHRS?

Do insiders & institutionals hold more shares of ALVO or CHRS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS vs. The Competition

Coherus Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools